Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QX027N in uncontrolled moderate-to-severe asthma
CTR20263765Phase 2Active
- Sponsor
- Quxin Biopharmaceutical
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QX027N in asthma, sponsored by Quxin Biopharmaceutical. Started Oct 2026; status: active.
02
Drugs
QX027N
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20263765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263765.